Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Recursion Pharmaceuticals Inc RXRX

Healthcare Biotechnology
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative... see more

Recent & Breaking News (NDAQ:RXRX)

Recursion to Participate in Upcoming Investor Conferences

PR Newswire March 2, 2022

Recursion to Participate in Upcoming Investor Conferences

PR Newswire February 8, 2022

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology

PR Newswire December 7, 2021

Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities

PR Newswire December 6, 2021

Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments

PR Newswire November 30, 2021

Recursion Provides Business Updates and Reports Third Quarter 2021 Financials

PR Newswire November 10, 2021

Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas

PR Newswire October 7, 2021

Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

PR Newswire September 29, 2021

Recursion Reports Second Quarter 2021 Financials and Provides Business Updates

PR Newswire August 13, 2021

Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD

PR Newswire July 13, 2021

Recursion Opens Child Care Center to Support Employees

PR Newswire July 12, 2021

Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City

PR Newswire July 1, 2021

Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery

Canada NewsWire June 23, 2021

Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery

Canada NewsWire June 15, 2021

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis

PR Newswire May 25, 2021

Recursion Reports First Quarter 2021 Financials and Provides Business Updates

PR Newswire May 12, 2021

Recursion Pharmaceuticals Announces Closing of Initial Public Offering

PR Newswire April 21, 2021

Recursion Pharmaceuticals Announces Pricing of Initial Public Offering

PR Newswire April 16, 2021